BioCentury
ARTICLE | Clinical News

Paloma preclinical data

March 14, 2011 7:00 AM UTC

In a mouse xenograft model of HRPC, Palomid 529 significantly reduced tumor volume vs. vehicle-treated controls at day 24 (p<0.05). Additionally, Palomid 529 plus cisplatin, Taxotere docetaxel or radiotherapy significantly reduced tumor volume compared to each therapy alone (p<0.05 for all). Data were presented at the American Association for Cancer Research meeting on Targeting PI3K/ mTOR Signaling in Cancer in San Francisco. ...